Tisdag 17 November | 19:57:32 Europe / Stockholm
Est. tid*
2027-02-03 08:00 Bokslutskommuniké 2026
2026-12-15 N/A Extra Bolagsstämma 2026
2026-11-04 - Kvartalsrapport 2026-Q3
2026-08-26 - Kvartalsrapport 2026-Q2
2026-06-18 - X-dag ordinarie utdelning CRNO B 0.00 SEK
2026-06-17 - Årsstämma
2026-05-27 - Kvartalsrapport 2026-Q1
2026-02-27 - Bokslutskommuniké 2025
2025-11-27 - Kvartalsrapport 2025-Q3
2025-08-27 - Kvartalsrapport 2025-Q2
2025-06-11 - X-dag ordinarie utdelning CRNO B 0.00 SEK
2025-06-10 - Årsstämma
2025-05-22 - Kvartalsrapport 2025-Q1
2025-02-25 - Bokslutskommuniké 2024
2024-11-21 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-29 - X-dag ordinarie utdelning CRNO B 0.00 SEK
2024-05-28 - Årsstämma
2024-05-23 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2023-12-12 - Extra Bolagsstämma 2023
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning CRNO B 0.00 SEK
2023-06-01 - Årsstämma
2023-05-22 - Kvartalsrapport 2023-Q1
2023-02-22 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-02 - X-dag ordinarie utdelning CRNO B 0.00 SEK
2022-06-01 - Årsstämma
2022-05-19 - Kvartalsrapport 2022-Q1
2022-02-28 - Extra Bolagsstämma 2022
2022-02-09 - Bokslutskommuniké 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-06-10 - X-dag ordinarie utdelning CRNO B 0.00 SEK
2021-06-09 - Årsstämma
2021-05-19 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-19 - Kvartalsrapport 2020-Q3
2020-09-29 - Extra Bolagsstämma 2020
2020-08-28 - Kvartalsrapport 2020-Q2
2020-06-11 - X-dag ordinarie utdelning CRNO B 0.00 SEK
2020-06-10 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-30 - Kvartalsrapport 2019-Q2
2019-08-28 - Extra Bolagsstämma 2019
2019-06-19 - Årsstämma
2019-06-12 - X-dag ordinarie utdelning CRNO B 0.00 SEK
2019-05-23 - Kvartalsrapport 2019-Q1
2019-02-22 - Bokslutskommuniké 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-30 - Kvartalsrapport 2018-Q2
2018-06-14 - X-dag ordinarie utdelning CRNO B 0.00 SEK
2018-06-13 - Årsstämma
2018-05-24 - Kvartalsrapport 2018-Q1
2018-04-19 - Extra Bolagsstämma 2018
2018-02-22 - Bokslutskommuniké 2017
2017-11-14 - Kvartalsrapport 2017-Q3
2017-08-23 - Kvartalsrapport 2017-Q2
2017-06-22 - X-dag ordinarie utdelning CRNO B 0.00 SEK
2017-06-21 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-02-22 - Bokslutskommuniké 2016
2016-11-11 - Kvartalsrapport 2016-Q3
2016-09-09 - Extra Bolagsstämma 2016
2016-08-24 - Kvartalsrapport 2016-Q2
LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Cereno Scientific är verksamt inom bioteknik. Bolaget är specialiserat inom läkemedelsutveckling av vanliga och sällsynta kardiovaskulära sjukdomar. Den främsta läkemedelskandidaten utvecklas för behandling av den sällsynta sjukdomen pulmonell arteriell hypertension, samt för trombosindikationer. Särskilt används epigenetisk modulering för att utveckla behandlingar för behövande patienter med kardiovaskulära sjukdomar. Cereno Scientifics huvudkontor ligger i Mölndal.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Cereno Scientific announces resignation of Chairperson of the Board at his own request

2026-11-17 17:11:00

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that Jeppe Øvlesen has informed the Board of Directors of his decision to resign as Chairperson and member of the Board at his own request, effective immediately.

“I have greatly valued my time as Chairperson of the Board of Cereno Scientific and the opportunity to work alongside Sten, his team and my fellow Board members. As the demands and responsibilities of the Chairperson role have increased, I have come to the conclusion that I am no longer best placed to fulfil the requirements of the position. I have therefore decided to step down. This decision does not change my confidence in the company’s science and the potential of its drug development programs. I wish Cereno and its team every success going forward,” said Jeppe Øvlesen.

“We respect Jeppe’s decision and thank him for his contributions and commitment during his time on the Board. We wish him every success in his future endeavors. Our focus remains on advancing Cereno’s drug development programs and executing our financing plans to support the company’s continued development,” said Sten R. Sörensen, CEO of Cereno Scientific.

According to Cereno Scientific’s Articles of Association, the Board of Directors shall consist of a minimum of four and a maximum of eight members. Following Jeppe Øvlesen’s resignation, the Board will consist of four members and will therefore continue to comply with the requirements of the Articles of Association. The Board will announce its designated Chairperson as soon as possible.